Trump Media seeks SEC approval for bitcoin and ethereum ETF
fund
that
will
invest in both bitcoin and ethereum, the two largest cryptocurrencies, according to a filing with the U.S. Securities and Exchange Commission on Monday. This marks the second cryptocurrency
ETF
filing from the
social media
company associated with President
Donald Trump
in less than two weeks. If approved, the Truth Social Bitcoin ETF and the Truth Social Bitcoin & Ethereum ETF would join a crowded and competitive market already dominated by a handful of established
asset
managers such as BlackRock, whose iShares Bitcoin ETF has $72.5 billion in assets.
"It will be a challenge for any new entrant in this market," said Bryan Armour, ETF analyst at Morningstar. "The only way to stand out will be through fees or brand."
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
When Knee Pain Hits, Start Eating These Foods, and Feel Your Pain Go Away (It's Genius)
12facts.com
Read More
The filing for the new bitcoin and ethereum ETF does not disclose proposed fees, and Trump Media has yet to reveal fees for the bitcoin ETF. Similar products have fees of 0.12%.
Crypto Tracker
TOP COIN SETS
Crypto Blue Chip - 5
-1.26%
Buy
DeFi Tracker
-1.33%
Buy
BTC 50 :: ETH 50
-1.47%
Buy
Web3 Tracker
-7.06%
Buy
AI Tracker
-8.19%
Buy
TOP COINS
(₹)
XRP
197 (
5.47%
)
Buy
Ethereum
226,895 (
3.33%
)
Buy
Solana
13,487 (
2.87%
)
Buy
Bitcoin
9,242,172 (
1.52%
)
Buy
BNB
56,541 (
1.33%
)
Buy
Trump Media representatives did not immediately respond to a request for comment. Armour noted that the latest filing spells out a specific allocation ratio between bitcoin and ethereum. The issuer, Yorkville America Digital, said it initially anticipates holding three bitcoins for every ethereum token in the ETF.
Did you Know?
The world of cryptocurrencies is very dynamic. Prices can go up or down in a matter of seconds. Thus, having reliable answers to such questions is crucial for investors.
View
Details
»
"There is little that is different about this new venture other than the way it could be marketed," said Sui Chung, CEO and chairman of CF Benchmarks. "Given Truth Social's involvement, it may very well be that (these) are marketed directly to individual investors and that this ends up getting attention from those investors in the same way that people who love their iPhones buy Apple stock."
Live Events
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
28 minutes ago
- Economic Times
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
Agencies Representative Image New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
The Hindu
28 minutes ago
- The Hindu
Structural cracks emerge in the India-U.S. strategic partnership
What is going wrong with India-U.S. ties, often celebrated by both sides as a definitive partnership of the 21st century? Is this just a glitch caused by a strident strain of American nationalism and its volatile champion, President Donald Trump, or is the current turmoil a sign of structural tensions that had been simmering beneath the rhetoric? Last week, only days ahead of the meltdown, this is how a State Department official described the prospects of ties with India to The Hindu: 'The U.S.-India relationship is both strong and a high priority for the administration. The U.S. has long-term, strategic interests in partnering with India, including cooperating on space, defence, energy, trade, and technology. In the first six months of this administration, President Trump and Prime Minister [Narendra] Modi announced the COMPACT Initiative, and we've seen numerous high-level touch points between our leaders from the White House to cabinet officials. This shows the dedication the Trump administration has to the U.S.-India relationship.' Watch | Analysing the economic and strategic impact of Trump's tariffs on India And then the cracks came out in the open, and how. While the above statement reflects an optimistic strand — Secretary of State Marco Rubio shares this view, going by his past statements — a more sceptical approach towards India is gaining currency among the influencers of American strategy in Washington DC. They point to structural factors that could derail the gains made after a nasty showdown between the two countries after Pokhran 2 in 1998. A recent article by Ashley J Tellis titled 'India's Great-Power Delusions' is an example. Mr. Tellis used to be a strong votary for American 'strategic altruism' towards India. Also Read | India, Russia can take their 'dead economies' down together: Trump Strategy in both India and the U.S. is now hostage to the fickle sentiments of respective nationalist audiences. In this game, the U.S. and India are not equal. There is a fundamental conflict between India's need to constantly advertise itself on the world stage and American scepticism of such power projections by anyone else, friend or foe. India used to maintain a benign strategic demeanour, articulating its ambitions in terms of human development, and carefully calibrating its claims for a larger global role. There was a bipartisan view that India's rise would be a global good. The rise of America First splintered American strategic outlook, and now only one part of it continues to be optimistic about India, while a strong strand is of concern. India sceptics These sceptics range from those who see an illiberal turn in India's trajectory to someone like Senator Lindsay Graham, a Trump acolyte. The India First foreign policy of Prime Minister Narendra Modi sought to be more assertive internationally and also adhere to — not abandon — India's traditional path of strategic autonomy. India's new normal, which predicts military strikes in response to terrorism, is difficult for the U.S. to encourage. The American fear of a nuclear flashpoint undermines India's status as a stabilising power. Mr. Trump is specially concerned about nuclear instability. As a superpower, the U.S. is proud of its capacity to have parallel partnerships with rival pairs — Qatar and Saudi Arabia-UAE, South Korea and Japan, India and Pakistan, for instance. It would argue that each relationship stands on its own individual context and merits. The U.S. would not appreciate the same logic thrown back at it by its partners, however, and India's relations with Iran and Russia have been of particular concern for it. While the U.S. does not like India questioning its ties with Pakistan, it questions India on its ties with Russia and Iran. India has interests in an increasing geographical spectrum of the planet, and its super power ambitions under Mr. Modi only heightens this desire of multiple alliances. According to External Affairs Minister S. Jaishankar, it is 'Sabka Saath, Sabka Vikas' — 'with all, development of all' - in foreign policy. 'India is among the few that can simultaneously engage with Russia and Ukraine, Israel and Iran, the democratic West and the Global South, and the BRICS and QUAD,' he said on March 23. This advantage of India could have been a currency in its relations with the U.S., and the world. But as it turns out, each one's relations with other countries is creating more rift in India-U.S. ties. A strategic lock-in within the U.S. does not sit well with Indian nationalism, and certainly not of with the Rashtriya Swayamsevak Sangh (RSS) which views the West with scepticism. India's neighbourhood, which is of critical interest for the U.S., is now again a source of tension between the two countries. Mr. Trump did not care much about India's ties with Russia, as he himself wanted to reset the U.S.-Russia relationship. With his hopes of mediating an end of the Ukraine war dimming, the one point of convergence between America First and India First lost traction. What is left is U.S. concerns about India's involvement with BRICS, Russia and Iran and India's resentment with the new thaw in U.S.-Pakistan relations. The Trump administration is, on the one hand, exploring a detente with China; and on the other, scaling up cooperation with Pakistan, partly to wean it off from Beijing. Pakistan is also back in American calculus as a counter terrorism partner — just at the moment India is trying to expose its support for terrorism. India has always leveraged its market in ties with the U.S. But protectionist measures increased in the recent years as India sought to build up its manufacturing sector. Indian market has remained an unrealisable dream for the U.S. By insisting on a complete opening up of the market, Mr. Trump has brought it to a head. These are all structural factors that take the shine off India-U.S. ties, a trade deal or not.
Time of India
28 minutes ago
- Time of India
Russia, India Vow Expand Trade Dies As Trump Mocks 'DEAD ECONOMIES' Amid Tariff War
India's state-owned oil refiners have paused purchases of Russian crude over the past week, a significant shift attributed to narrowing price discounts and mounting pressure from the US President Donald Trump, reports Reuters. India, the world's third-largest oil importer and the largest buyer of seaborne Russian crude, is now turning to alternative sources to meet its energy demands. Sources familiar with the refiners' procurement plans told Reuters that major state entities including Indian Oil Corp (IOC), Hindustan Petroleum Corp (HPCL), Bharat Petroleum Corp (BPCL), and Mangalore Refinery and Petrochemical Ltd (MRPL) have not sought Russian crude in approximately the last seven days. Watch. Read More
